Welcome to our dedicated page for Frontage Hldgs news (Ticker: FTHCY), a resource for investors and traders seeking the latest updates and insights on Frontage Hldgs stock.
Frontage Holdings Corporation reports developments tied to its global contract research organization operations through Frontage Laboratories, Inc. The company provides integrated drug-development services for biopharmaceutical clients, including drug metabolism and pharmacokinetics, analytical testing and formulation development, clinical trial material manufacturing, bioanalysis, preclinical safety and toxicology assessment, and early phase clinical studies.
Recurring news for FTHCY includes CRDMO facility expansion, regional operating leadership in Canada and Asia-Pacific, completed acquisitions that add bioanalytical, DMPK, analytical chemistry, microbiology and toxicology capabilities, and collaborations involving early phase clinical trial services.
Frontage Holdings Corporation (OTC:FTHCY) has announced the appointment of Dr. Abdul Mutlib as President of Frontage Laboratories, Canada, marking a strategic expansion of its services in the Canadian market. Dr. Mutlib, who will continue his role as Chief Scientific & Strategy Officer, will oversee operations in Toronto and Vancouver, reporting to Co-CEO Dr. Wentao Zhang.
With over 35 years of R&D experience in pharmaceutical and CRO sectors, Dr. Mutlib will focus on establishing Frontage as a key partner for Canada's growing biotech industry. The appointment aligns with Frontage's strategy to enhance its position as a leading global pharmaceutical Contract Research Organization (CRO).
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Frontage Holdings Corporation has announced the promotions of Dr. Abdul Mutlib to CEO and Dr. John Lin to President as of January 3, 2023. Dr. Mutlib has over 12 years of experience with Frontage, leading the Preclinical business, while Dr. Lin has been with the company for over 15 years, focusing on Bioanalytical and Biologics services. Founder Dr. Song Li remains Executive Chairman, emphasizing a focus on strategic growth. The leadership changes aim to enhance operational performance and prepare for future expansion, leveraging their extensive industry experience.
Frontage Laboratories announced a collaboration with Eisai and Biogen to support the bioanalysis of lecanemab (BAN2401) in a phase 3 study for Alzheimer's disease.
The study met aggressive timelines, showcasing Frontage's commitment to addressing medical needs. Notably, the study has delivered favorable results as highlighted in a presentation on November 29, 2022.
Frontage's scientific team contributed to biomarker analysis, reinforcing their role in global clinical research.